We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The device is used with the company’s AcQMap system, a stand-alone platform that captures the cardiac-imaging information and visually displays the electrical patterns. Read More
Eli Lilly has entered into a global partnership with Amgen to increase supply capacity for Eli Lilly’s neutralizing antibodies as a treatment for COVID-19 patients. Read More
The National Institutes of Health (NIH) has launched a phase 2 clinical trial of Rigel Pharmaceuticals’ fostamatinib for the treatment of hospitalized COVID-19 patients. Read More
Co-developers Pfizer and BioNTech are preparing for a global roll-out of the vaccine as soon as it receives an Emergency Use Authorization or approval. Read More
Indian pharmaceutical company Dr. Reddy’s will assist in phase 3 clinical trials and distribution in India for Russia’s COVID-19 vaccine, Sputnik V, the company and Russian government announced. Read More
Pfizer reported early safety data yesterday from its phase 3 COVID-19 vaccine trial, saying the vaccine prompted mostly mild to moderate adverse reactions in patients. Read More
A mid-stage trial of Eli Lilly’s neutralizing COVID-19 monoclonal antibody LY-CoV555 found that the drug reduced the risk of hospitalization in mild-to-moderate COVID-19 patients by 72 percent compared to a placebo. Read More
Health regulators abroad have begun giving the OK for AstraZeneca to resume its phase 3 COVID-19 vaccine trial following a single unexplained patient illness, but the FDA has still not cleared the trial to start back up, with FDA Commissioner Stephen Hahn saying the agency will engage in “very significant work” with the company to unravel the safety issue. Read More
Distribution of a COVID-19 vaccine in the U.S. will begin within 24 hours of getting the go-ahead from regulators, under a new distribution plan unveiled yesterday by HHS. Read More